
Health experts warn Trump cuts to the CDC could hurt overdose prevention: ‘A step backwards'
US overdose deaths began to decline for the first time in 2023 after climbing for over two decades.
The CDC's Overdose Data to Action (OD2A) cooperative agreement, launched in 2019 during the first Trump administration, provides funding for overdose 'prevention and surveillance strategies'. Public health officials emphasized to the Guardian that to effectively reduce fatal overdoses, agencies must work in tandem to track substance use disorders, overdoses and changes in the drug supply, and to implement interventions, like distributing the overdose reversal drug naloxone. OD2A funding made this kind of robust response possible.
The Biden administration expanded the program in 2023, giving five year grants to 90 state and local public health departments.
'The funding has largely been used for surveillance, in other words, to obtain data on the opioid crisis that informs a public health response to the problem,' said Dr Andrew Kolodny, medical director for the Opioid Policy Research Collaborative at Brandeis University.
'In general, our surveillance data for the opioid crisis is awful. I would even say that one of the reasons that the opioid crisis is as severe as it is, and why, up until recently, overdose deaths have continued to go up pretty much year after year for about 25 years, is because we had very poor surveillance of the problem.'
But now, health officials worry the money could run out at the end of the first two year cycle on 1 September.
Dr Jenny Hua, interim deputy commissioner for Chicago's department of public health (CDPH), which receives $3.4m annually in OD2A funding, says they're preparing for the worst.
'We are doing scenario planning. The preferred scenario is that we have the entire award starting the first of August,' she said, though she's uncertain whether that's likely.
Hua noted that what she's been 'told about this money is that at least half of it is available next year. The problem is that for a number of [the CDC's] cooperative agreements with local health departments and state health departments, they're receiving that money in monthly increments, which has never happened before.'
She also said that the CDC now doesn't have enough money at once to distribute.
A Department of Health and Human Services spokesperson said in a statement that CDC is committed to the O2DA program and that: 'We are working closely with our funding partners to make within the next month, at a minimum, initial grant awards, which may contain less than the full-year of funding in the first incremental award … This incremental funding approach is not specific to OD2A.'
Hua said 'that sort of fog is making it incredibly difficult for us to make funding decisions, to allocate our resources.'
The CDPH has used OD2A funding to make same day substance use disorder treatment available to patients through telehealth, and had plans to expand recovery housing for treatment.
'Do you pull the plug? What tea leaves are we supposed to read, to know what course of action to take?' Hao wondered.
Kolodny said it's especially important to keep funding surveillance of multiple factors related to overdose deaths because 'right now, you can talk to five different experts, and you'll get five different explanations for why the deaths are coming down. Nobody really knows, right? And that's because we don't have good surveillance data,' he said, 'and it's about to get worse.'
Surveillance means tracking not only the number of fatal and non-fatal overdoses in the US, but also the prevalence of substance use disorders, including opioid use disorder. Historically, this has been the mission of the Substance Abuse and Mental Health Services Administration (Samhsa), which also provides a plethora of other addiction and overdose prevention services, but that agency also faces funding cuts.
OD2A funding also went towards surveillance of 'emergency drug threats' which often comes in the form of new adulterants in the street drug supply. Unexpected substances, including tranquilizers like xylazine, and potent synthetic opioids like nitazenes and carfentanil, can cause overdoses and poisonings that are more dangerous because they aren't yet well understood.
Still, many health departments across the country do not monitor the street drug supply.
Street drug surveillance can help officials intervene rapidly when overdoses increase. Partly thanks to OD2A funding, Chicago health officials immediately became aware of a spike in overdoses on the city's west side last May.
Lab analysis revealed the spike was related to the presence of medetomidine, a potent veterinary tranquilizer, in the street drug supply. In June, the CDPH launched the Summer Opioid Response Incident Command System, a coordinated effort involving public messaging about the contaminated drug supply, distribution of naloxone and drug testing kits, and expanding access to treatment. This effort reduced overdose related emergency responses by 23% last summer compared to the year before, according to a report on the program.
The Los Angeles department of public health also uses OD2A funding for 'community-based drug checking', according to a statement from a spokesperson; 'The Los Angeles County Department of Public Health recently announced a 22% decline in drug-related overdose deaths and poisonings in 2024, the most significant drop in LA County history,' adding that 'the CDC Overdose to Action LOCAL grant award contributed to these successes.'
A spokesperson for the Maryland department of health said that cuts could mean layoffs for 28 public health workers, which would mean they no longer have the capacity to track non-fatal overdoses and will lose most of their capacity to track fatal overdoses.
Tracking the number of people who die of overdoses is the 'bare minimum' of surveillance, according to Kolodny, who noted that funding cuts are 'frustrating' to witness.
'Trump has been especially popular in some of the regions of the country that have suffered most from the opioid crisis. So one might think that his administration would be doing everything it can to bring this problem to an end. And in my opinion, this is a step backwards,' he said.
Funding overdose prevention doesn't just save lives, it also saves money, Kolodny said: 'The opioid crisis is a trillion dollar a year problem, and I'm not making up that number. That's a number that comes in part from the cost analysis on the number of lives that are lost.'
Lives will continue to be lost until we can really understand what drives overdose deaths, Kolodny said: 'Without the data, we're shooting in the dark.'

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Daily Mail
2 hours ago
- Daily Mail
Scientists reveal the REAL number of daily steps you should aim for to prevent dementia
Experts, influencers and fitness trackers have long touted 10,000 steps a day as the 'perfect' number to ward off obesity, cancer and early death. However, 10,000 steps, equivalent to five miles, might not be the magic number. In fact, researchers in Australia suggest aiming lower. In a new analysis of nearly 60 studies, researchers found just 7,000 steps in a day was enough to lower the risk of dementia, heart disease and some forms of cancer. This adds up to roughly 3.5 miles. Scientists compared the effects of 7,000 daily steps to 2,000. Based on health data from 160,000 people, those who walked 7,000 steps a day had a 25 percent lower risk of cardiovascular disease, America's number one killer. Additionally, 7,000 daily steps led to a 38 percent drop in dementia risk. People who adhered to the measure were also less likely to suffer from depression than those who got just 2,000 steps in a day. And though the average American only takes about 4,000 to 5,000 daily steps, according to the CDC, researchers said even this level of activity could lead to lower chronic disease risk. It's unclear exactly how walking prevents cancer, dementia and other chronic diseases, but it's thought to be due to regulating hormone levels and lowering the risk of obesity, which is consistently linked to lasting health issues. Exercise in general, including walking, has been proven to lower chronic disease risk, and walking in particular can burn about 100 to 200 calories per mile and improve joint, heart and brain health. Dr Melody Ding, lead study author and epidemiologist at the University of Sydney, said: 'We have this perception we should be doing 10,000 steps a day, but it's not evidence based.' The figure dates back to a marketing campaign in Japan centered around the 1964 Tokyo Olympics. At the time a brand of pedometer launched called the manpo-kei, which translates to '10,000-step meter.' Dr Ding said that figure was then 'taken out of context' and became an unofficial guideline, even for modern-day fitness trackers and apps. However, she noted it's still important not to discourage people who are already surpassing 10,000 steps to cut back if they don't have to. She said this is because 'it's not that after 7,000 steps it becomes harmful.' The idea is that 7,000 is just 'a lot more accessible and approachable' for more people. The new research, published this week in The Lancet Public Health, analyzed 57 studies conducted between 2014 and 2025. The studies included data on the risk of all-cause death, cardiovascular disease, cancer, type 2 diabetes, cognitive outcomes, mental health outcomes, physical function and falls. Overall, people who walked at least 7,000 steps every 24 hours were at a 25 percent lower risk of developing cardiovascular disease and 47 percent lower risk of dying from it compared to people who got 2,000 steps a day. Additionally, those in the higher step count group were six percent less likely to develop cancer overall and 37 percent less likely to die from it, though the study did not distinguish between specific forms of the disease. The 7,000 step benchmark could also reduce the likelihood of developing dementia by 38 percent and depression by 22 percent. The chance of dying from any cause also decreased 47 percent in people who walked 7,000 steps a day compared to 2,000. Walking may help fend off disease by decreasing the risk of obesity, which is tied to heart disease, diabetes, depression, dementia and some forms of cancer. It also has been shown to improve blood flow to the brain and reduce inflammation, key preventative techniques against dementia. Additionally, walking lowers levels of hormones like estrogen and insulin, which can fuel breast, ovarian, endometrial and pancreatic cancers, among others. And it even releases feel-good endorphins, natural chemicals that boost mood and promote a sense of well-being. Dr Ding said if 7,000 still feels too ambitious, aiming for a more reasonable number like 4,000 could also lower the risk of all-cause mortality by as much as 36 percent compared to 2,000 steps. With this in mind, she encouraged moving as much as possible within limits. There were several limitations to the new study, including lack of data on specific participant factors like sex, race, ethnicity, age, weight and overall health status. Additionally, many of the studies included only measured differences for several weeks or months, so there was a lack of long-term data.


Reuters
3 hours ago
- Reuters
GSK's blood cancer drug gets EU approval
July 24 (Reuters) - The European Union has approved GSK's (GSK.L), opens new tab drug Blenrep to treat relapsed or treatment-resistant forms of a cancer affecting blood plasma cells, the British drugmaker said on Thursday. EU regulators approved Blenrep after phase III trials showed the drug, when used in combination with standard treatments, extended progression-free survival and improved overall survival in patients with relapsed or refractory multiple myeloma, GSK said. The approval comes a day after the U.S. Food and Drug Administration extended its review of the drug as a combination treatment for the same illness. The FDA's panel of independent experts had last week recommended against the drug, citing concerns about previously documented risks of eye-related side effects. The EU approval marks the sixth regulatory nod for Blenrep combinations, with applications still under review across all major markets. The drug delivers a cell-killing agent directly to tumour cells while limiting damage to healthy tissue — unlike conventional chemotherapy. Multiple myeloma is the third most common blood cancer globally and is generally considered treatable but not curable. It affects the immunity-boosting plasma white blood cells.


Daily Mail
4 hours ago
- Daily Mail
Hulk Hogan dead at 71: WWE icon passes away in Florida as cause of death revealed
Wrestling legend Hulk Hogan has died aged 71. The WWE icon passed away early Thursday morning after medics were dispatched to his Clearwater, Florida home, per TMZ. Operators stated was regarding a cardiac arrest. has contacted representatives for Hulk Hogan for comment.